[
  {
    "ts": null,
    "headline": "Edwards Wavers Analysts Debate Its Earnings Miss Amid Hefty TAVR Investments",
    "summary": "Edwards Lifesciences stock wavered Wednesday, though the heart-valve replacement maker issued a bullish outlook for 2026.",
    "url": "https://finnhub.io/api/news?id=0fd23c2dc8d557b45f53810102c912fc90a6bca4ef6f3c6fb0af201e96974a84",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770844043,
      "headline": "Edwards Wavers Analysts Debate Its Earnings Miss Amid Hefty TAVR Investments",
      "id": 139049635,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "EW",
      "source": "Yahoo",
      "summary": "Edwards Lifesciences stock wavered Wednesday, though the heart-valve replacement maker issued a bullish outlook for 2026.",
      "url": "https://finnhub.io/api/news?id=0fd23c2dc8d557b45f53810102c912fc90a6bca4ef6f3c6fb0af201e96974a84"
    }
  },
  {
    "ts": null,
    "headline": "Unusual volume S&P500 stocks in Wednesday's session",
    "summary": "In today's session, there are S&P500 stocks with remarkable trading volume. Explore the stocks exhibiting unusual volume in Wednesday's session.",
    "url": "https://finnhub.io/api/news?id=033c5014df7c27f24f0c5a6c10ab1fc5c81841acbdd49f4222e3e47a86487724",
    "source": "ChartMill",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770833104,
      "headline": "Unusual volume S&P500 stocks in Wednesday's session",
      "id": 139047010,
      "image": "https://www.chartmill.com/images/uploads/CM_Unusual_Volume_Small_free_b9d2e60841.webp",
      "related": "EW",
      "source": "ChartMill",
      "summary": "In today's session, there are S&P500 stocks with remarkable trading volume. Explore the stocks exhibiting unusual volume in Wednesday's session.",
      "url": "https://finnhub.io/api/news?id=033c5014df7c27f24f0c5a6c10ab1fc5c81841acbdd49f4222e3e47a86487724"
    }
  },
  {
    "ts": null,
    "headline": "Options Corner: Edwards Lifesciences Poor Start To The New Year Offers A Contrarian Opportunity",
    "summary": "With Edwards Lifesciences getting a key earnings report out of the way, the uncertainties hanging over EW stock has cleared for the bulls.",
    "url": "https://finnhub.io/api/news?id=c99f6bcbccc82d4467af91b3bbcb6e4888b332eda28d3e289e2aa91c18ed2241",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770832968,
      "headline": "Options Corner: Edwards Lifesciences Poor Start To The New Year Offers A Contrarian Opportunity",
      "id": 139057683,
      "image": "https://cdn.benzinga.com/files/images/story/2026/02/11/Irvine--California---7-May-2023-Edwards-.jpeg?width=2048&height=1536",
      "related": "EW",
      "source": "Benzinga",
      "summary": "With Edwards Lifesciences getting a key earnings report out of the way, the uncertainties hanging over EW stock has cleared for the bulls.",
      "url": "https://finnhub.io/api/news?id=c99f6bcbccc82d4467af91b3bbcb6e4888b332eda28d3e289e2aa91c18ed2241"
    }
  },
  {
    "ts": null,
    "headline": "Edwards Lifesciences 2026 Growth Targets Achievable, RBC Says",
    "summary": "Edwards Lifesciences' (EW) high-end guidance targets for 2026 are achievable given multiple catalyst",
    "url": "https://finnhub.io/api/news?id=f0e90cfa8a50bcf9bb2b44a7a5c63345a054b369c0ebd37b476bdd3a4cabc1ac",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770831412,
      "headline": "Edwards Lifesciences 2026 Growth Targets Achievable, RBC Says",
      "id": 139046648,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "EW",
      "source": "Yahoo",
      "summary": "Edwards Lifesciences' (EW) high-end guidance targets for 2026 are achievable given multiple catalyst",
      "url": "https://finnhub.io/api/news?id=f0e90cfa8a50bcf9bb2b44a7a5c63345a054b369c0ebd37b476bdd3a4cabc1ac"
    }
  },
  {
    "ts": null,
    "headline": "Edwards Lifesciences Corp. stock outperforms competitors on strong trading day",
    "summary": "Edwards Lifesciences Corp. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=ccc849df61808c5073d3a2d32b399e3a0104c372821a054a999e8de699832572",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770828720,
      "headline": "Edwards Lifesciences Corp. stock outperforms competitors on strong trading day",
      "id": 139068599,
      "image": "",
      "related": "EW",
      "source": "MarketWatch",
      "summary": "Edwards Lifesciences Corp. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=ccc849df61808c5073d3a2d32b399e3a0104c372821a054a999e8de699832572"
    }
  },
  {
    "ts": null,
    "headline": "Edwards Slips As Analysts Debate Its Earnings Miss Amid Hefty TAVR Investments",
    "summary": "Edwards Lifesciences stock reversed lower Wednesday, though the heart-valve replacement maker issued a bullish outlook for 2026.",
    "url": "https://finnhub.io/api/news?id=4d1d6ff15ca9242d8c19f3cdc9c0e46027df561af1db01b77467d657dc1f2d28",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770825618,
      "headline": "Edwards Slips As Analysts Debate Its Earnings Miss Amid Hefty TAVR Investments",
      "id": 139046649,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "EW",
      "source": "Yahoo",
      "summary": "Edwards Lifesciences stock reversed lower Wednesday, though the heart-valve replacement maker issued a bullish outlook for 2026.",
      "url": "https://finnhub.io/api/news?id=4d1d6ff15ca9242d8c19f3cdc9c0e46027df561af1db01b77467d657dc1f2d28"
    }
  },
  {
    "ts": null,
    "headline": "Goldman Sachs Maintains Buy on Edwards Lifesciences, Lowers Price Target to $95",
    "summary": "Goldman Sachs  analyst David Roman   maintains Edwards Lifesciences (NYSE:EW) with a Buy and lowers the price target from $108 to $95.",
    "url": "https://finnhub.io/api/news?id=b513a2d1187bcede6d4b52fcedb9acb323927bac136308c9ae19cc0abeaf9f77",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770817306,
      "headline": "Goldman Sachs Maintains Buy on Edwards Lifesciences, Lowers Price Target to $95",
      "id": 139057684,
      "image": "",
      "related": "EW",
      "source": "Benzinga",
      "summary": "Goldman Sachs  analyst David Roman   maintains Edwards Lifesciences (NYSE:EW) with a Buy and lowers the price target from $108 to $95.",
      "url": "https://finnhub.io/api/news?id=b513a2d1187bcede6d4b52fcedb9acb323927bac136308c9ae19cc0abeaf9f77"
    }
  },
  {
    "ts": null,
    "headline": "Edwards Lifesciences Corporation Q4 2025 Earnings Call Summary",
    "summary": "Moby summary of Edwards Lifesciences Corporation's Q4 2025 earnings call",
    "url": "https://finnhub.io/api/news?id=f5e4002d4226e4271d597d7c78bf57ad4065fd26a9ec61c07c274704a9cc55b9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770816600,
      "headline": "Edwards Lifesciences Corporation Q4 2025 Earnings Call Summary",
      "id": 139056266,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "EW",
      "source": "Yahoo",
      "summary": "Moby summary of Edwards Lifesciences Corporation's Q4 2025 earnings call",
      "url": "https://finnhub.io/api/news?id=f5e4002d4226e4271d597d7c78bf57ad4065fd26a9ec61c07c274704a9cc55b9"
    }
  },
  {
    "ts": null,
    "headline": "EW's Q4 Earnings Miss Estimates, Revenues Up Y/Y, Stock Climbs",
    "summary": "Edwards' Q4 EPS lags estimates but revenues top as TAVR and TMTT surge. Shares rise with 2026 sales growth seen at 8%-10%.",
    "url": "https://finnhub.io/api/news?id=ee995b01e80b788b469ebcb175fc24cefa8f64b4843b0cd6f9099c22364ff7d5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770815820,
      "headline": "EW's Q4 Earnings Miss Estimates, Revenues Up Y/Y, Stock Climbs",
      "id": 139045249,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "EW",
      "source": "Yahoo",
      "summary": "Edwards' Q4 EPS lags estimates but revenues top as TAVR and TMTT surge. Shares rise with 2026 sales growth seen at 8%-10%.",
      "url": "https://finnhub.io/api/news?id=ee995b01e80b788b469ebcb175fc24cefa8f64b4843b0cd6f9099c22364ff7d5"
    }
  },
  {
    "ts": null,
    "headline": "Piper Sandler Reiterates Overweight on Edwards Lifesciences, Raises Price Target to $100",
    "summary": "Piper Sandler  analyst Adam Maeder   reiterates Edwards Lifesciences (NYSE:EW) with a Overweight and raises the price target from $98 to $100.",
    "url": "https://finnhub.io/api/news?id=31b6fa06c254161842d086ab53b39680b204ab847c8e704dd0b2424dd73de54d",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770815145,
      "headline": "Piper Sandler Reiterates Overweight on Edwards Lifesciences, Raises Price Target to $100",
      "id": 139057685,
      "image": "",
      "related": "EW",
      "source": "Benzinga",
      "summary": "Piper Sandler  analyst Adam Maeder   reiterates Edwards Lifesciences (NYSE:EW) with a Overweight and raises the price target from $98 to $100.",
      "url": "https://finnhub.io/api/news?id=31b6fa06c254161842d086ab53b39680b204ab847c8e704dd0b2424dd73de54d"
    }
  },
  {
    "ts": null,
    "headline": "Edwards reports strong 2025 despite Q4 EPS miss",
    "summary": "Edwards’ financials reveal that its transcatheter mitral and tricuspid therapies (TMTT) portfolio grew by 56.4% in 2025.",
    "url": "https://finnhub.io/api/news?id=dbbffad752158a11f073b5855f2d20b3dcf943e776de23dea61c034c3ce31abd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770813858,
      "headline": "Edwards reports strong 2025 despite Q4 EPS miss",
      "id": 139042552,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "EW",
      "source": "Yahoo",
      "summary": "Edwards’ financials reveal that its transcatheter mitral and tricuspid therapies (TMTT) portfolio grew by 56.4% in 2025.",
      "url": "https://finnhub.io/api/news?id=dbbffad752158a11f073b5855f2d20b3dcf943e776de23dea61c034c3ce31abd"
    }
  },
  {
    "ts": null,
    "headline": "Truist Securities Maintains Hold on Edwards Lifesciences, Lowers Price Target to $89",
    "summary": "Truist Securities  analyst Richard Newitter   maintains Edwards Lifesciences (NYSE:EW) with a Hold and lowers the price target from $92 to $89.",
    "url": "https://finnhub.io/api/news?id=9af1d13b66a1f5fec81854e2d7e82d4549226b9044a35e9c78d435a707f742a7",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770812501,
      "headline": "Truist Securities Maintains Hold on Edwards Lifesciences, Lowers Price Target to $89",
      "id": 139057686,
      "image": "",
      "related": "EW",
      "source": "Benzinga",
      "summary": "Truist Securities  analyst Richard Newitter   maintains Edwards Lifesciences (NYSE:EW) with a Hold and lowers the price target from $92 to $89.",
      "url": "https://finnhub.io/api/news?id=9af1d13b66a1f5fec81854e2d7e82d4549226b9044a35e9c78d435a707f742a7"
    }
  },
  {
    "ts": null,
    "headline": "Why The Narrative Around Edwards Lifesciences EW Is Shifting After 2026 Outlook And JenaValve Setback",
    "summary": "Behind the small move in Edwards Lifesciences’ fair value estimate from about US$97.02 to about US$97.11 is a set of fine tuned assumptions that reflect the latest 2026 outlook and the fallout from the canceled JenaValve deal. Analysts are essentially sharpening their pencils on discount rates and revenue growth rather than rewriting the story. This suggests the market is focused on execution details, not a new thesis. Stay tuned to see how you can track these incremental model shifts and...",
    "url": "https://finnhub.io/api/news?id=fcf47552a498eab056ab34f455df50593bde73820585defeb8c3ae331e264cb9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770808201,
      "headline": "Why The Narrative Around Edwards Lifesciences EW Is Shifting After 2026 Outlook And JenaValve Setback",
      "id": 139041153,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "EW",
      "source": "Yahoo",
      "summary": "Behind the small move in Edwards Lifesciences’ fair value estimate from about US$97.02 to about US$97.11 is a set of fine tuned assumptions that reflect the latest 2026 outlook and the fallout from the canceled JenaValve deal. Analysts are essentially sharpening their pencils on discount rates and revenue growth rather than rewriting the story. This suggests the market is focused on execution details, not a new thesis. Stay tuned to see how you can track these incremental model shifts and...",
      "url": "https://finnhub.io/api/news?id=fcf47552a498eab056ab34f455df50593bde73820585defeb8c3ae331e264cb9"
    }
  },
  {
    "ts": null,
    "headline": "Wells Fargo Maintains Overweight on Edwards Lifesciences, Raises Price Target to $100",
    "summary": "Wells Fargo  analyst Larry Biegelsen   maintains Edwards Lifesciences (NYSE:EW) with a Overweight and raises the price target from $96 to $100.",
    "url": "https://finnhub.io/api/news?id=d0ce1b24f4093af3293c0f6c68adcfcc3f2d3b4261df554fe620ef64044e7cad",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770807505,
      "headline": "Wells Fargo Maintains Overweight on Edwards Lifesciences, Raises Price Target to $100",
      "id": 139057687,
      "image": "",
      "related": "EW",
      "source": "Benzinga",
      "summary": "Wells Fargo  analyst Larry Biegelsen   maintains Edwards Lifesciences (NYSE:EW) with a Overweight and raises the price target from $96 to $100.",
      "url": "https://finnhub.io/api/news?id=d0ce1b24f4093af3293c0f6c68adcfcc3f2d3b4261df554fe620ef64044e7cad"
    }
  },
  {
    "ts": null,
    "headline": "February 2026's Undervalued Small Caps With Insider Action In Global Markets",
    "summary": "In February 2026, global markets are experiencing a dynamic shift as small-cap and value-oriented stocks make gains amid a cooling U.S. labor market and volatility in large-cap technology shares. With the S&P MidCap 400 and Russell 2000 indices showing solid performance, investors are increasingly interested in small-cap opportunities that demonstrate resilience and potential for growth. In this context, identifying a good stock often involves looking at companies with strong fundamentals...",
    "url": "https://finnhub.io/api/news?id=0bcd1bd562d2414b612e6ffcbe78b8981a2b76bff90a66669ab2d88a3d510c0c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770802779,
      "headline": "February 2026's Undervalued Small Caps With Insider Action In Global Markets",
      "id": 139041154,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "EW",
      "source": "Yahoo",
      "summary": "In February 2026, global markets are experiencing a dynamic shift as small-cap and value-oriented stocks make gains amid a cooling U.S. labor market and volatility in large-cap technology shares. With the S&P MidCap 400 and Russell 2000 indices showing solid performance, investors are increasingly interested in small-cap opportunities that demonstrate resilience and potential for growth. In this context, identifying a good stock often involves looking at companies with strong fundamentals...",
      "url": "https://finnhub.io/api/news?id=0bcd1bd562d2414b612e6ffcbe78b8981a2b76bff90a66669ab2d88a3d510c0c"
    }
  },
  {
    "ts": null,
    "headline": "The Analyst Verdict: Edwards Lifesciences In The Eyes Of 21 Experts",
    "summary": "",
    "url": "https://finnhub.io/api/news?id=26363eea7b1d6eb8a7261da81e8dc1247d6edb1de9ce1a6be5db0bdf432044fb",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770796833,
      "headline": "The Analyst Verdict: Edwards Lifesciences In The Eyes Of 21 Experts",
      "id": 139042053,
      "image": "https://cdn.benzinga.com/files/images/story/2025/11/06/analyst_ratings_6.jpg?width=2048&height=1536",
      "related": "EW",
      "source": "Benzinga",
      "summary": " ",
      "url": "https://finnhub.io/api/news?id=26363eea7b1d6eb8a7261da81e8dc1247d6edb1de9ce1a6be5db0bdf432044fb"
    }
  },
  {
    "ts": null,
    "headline": "BTIG Reiterates Buy on Edwards Lifesciences, Maintains $103 Price Target",
    "summary": "BTIG  analyst Marie Thibault   reiterates Edwards Lifesciences (NYSE:EW) with a Buy and maintains $103 price target.",
    "url": "https://finnhub.io/api/news?id=3421a2831e2c979cb6e76b3fd1e4ea09a09e013c04f622d80f2bd7de2b7ac704",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770794135,
      "headline": "BTIG Reiterates Buy on Edwards Lifesciences, Maintains $103 Price Target",
      "id": 139042054,
      "image": "",
      "related": "EW",
      "source": "Benzinga",
      "summary": "BTIG  analyst Marie Thibault   reiterates Edwards Lifesciences (NYSE:EW) with a Buy and maintains $103 price target.",
      "url": "https://finnhub.io/api/news?id=3421a2831e2c979cb6e76b3fd1e4ea09a09e013c04f622d80f2bd7de2b7ac704"
    }
  },
  {
    "ts": null,
    "headline": "Edwards Lifesciences Corp (EW) Q4 2025 Earnings Call Highlights: Strong Sales Growth Amidst ...",
    "summary": "Edwards Lifesciences Corp (EW) reports robust Q4 2025 results with an 11.6% sales increase, while navigating challenges in EPS and strategic spending.",
    "url": "https://finnhub.io/api/news?id=f3108da8165abe475f1846e78700815d40065a75cc6a75bfa9388a28ad0c5d31",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770786062,
      "headline": "Edwards Lifesciences Corp (EW) Q4 2025 Earnings Call Highlights: Strong Sales Growth Amidst ...",
      "id": 139039479,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "EW",
      "source": "Yahoo",
      "summary": "Edwards Lifesciences Corp (EW) reports robust Q4 2025 results with an 11.6% sales increase, while navigating challenges in EPS and strategic spending.",
      "url": "https://finnhub.io/api/news?id=f3108da8165abe475f1846e78700815d40065a75cc6a75bfa9388a28ad0c5d31"
    }
  },
  {
    "ts": null,
    "headline": "Edwards Lifesciences Q4 Earnings Call Highlights",
    "summary": "Edwards Lifesciences (NYSE:EW) reported fourth-quarter and full-year 2025 results that management characterized as strong, driven by continued momentum in transcatheter aortic valve replacement (TAVR) and rapid growth in transcatheter mitral and tricuspid therapies (TMTT). The company said fourth-qu",
    "url": "https://finnhub.io/api/news?id=281c58ce18e74bc762507e4f74c6f4a16bc5e090a8b16aca3ba50984b21bdd99",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770779238,
      "headline": "Edwards Lifesciences Q4 Earnings Call Highlights",
      "id": 139038922,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "EW",
      "source": "Yahoo",
      "summary": "Edwards Lifesciences (NYSE:EW) reported fourth-quarter and full-year 2025 results that management characterized as strong, driven by continued momentum in transcatheter aortic valve replacement (TAVR) and rapid growth in transcatheter mitral and tricuspid therapies (TMTT). The company said fourth-qu",
      "url": "https://finnhub.io/api/news?id=281c58ce18e74bc762507e4f74c6f4a16bc5e090a8b16aca3ba50984b21bdd99"
    }
  }
]